# A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05297890/  
OnCo record `nct05297890` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Lorlatinib in non-small-cell lung cancer and small-cell lung cancer, run by CStone Pharmaceuticals, active and no longer recruiting.

## Summary

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05297890 by CStone Pharmaceuticals, with 70 participants enrolled, started 2022-05-27 and due to reach its primary completion in 2023-12-26. Interventions recorded: Lorlatinib. Conditions listed: Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05297890
- Phase: 2
- Setting: A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer Subjects in China
- Sponsor: CStone Pharmaceuticals
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT05297890: https://clinicaltrials.gov/study/NCT05297890

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Lorlatinib](https://onco.cc/drugs/lorlatinib/)
- companies: [CStone Pharmaceuticals](https://onco.cc/companies/cstone/)

---
JSON: https://onco.cc/api/v1/entities/nct05297890.json